Claudia R Ball

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3233092/publications.pdf

Version: 2024-02-01

42 papers

4,673 citations

331670
21
h-index

289244 40 g-index

43 all docs 43 docs citations

43 times ranked

6775 citing authors

#	Article	IF	CITATIONS
1	Tumororganoide als prÅ⊭linische Tumormodelle – Implikationen fŽr Knochen- und Weichteiltumore. Osteologie, 2022, 31, 71-72.	0.1	O
2	Rational design of aqueous conjugated polymer nanoparticles as potential theranostic agents of breast cancer. Materials Chemistry Frontiers, 2021, 5, 4950-4962.	5.9	7
3	Functional States in Tumor-Initiating Cell Differentiation in Human Colorectal Cancer. Cancers, 2021, 13, 1097.	3.7	11
4	The balance between the intronic miR-342 and its host gene Evl determines hematopoietic cell fate decision. Leukemia, 2021, 35, 2948-2963.	7.2	9
5	Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer. Cell Reports, 2021, 36, 109394.	6.4	41
6	YAPâ€induced Ccl2 expression is associated with a switch in hepatic macrophage identity and vascular remodelling in liver cancer. Liver International, 2021, 41, 3011-3023.	3.9	17
7	YAP Orchestrates Heterotypic Endothelial Cell Communication via HGF/c-MET Signaling in Liver Tumorigenesis. Cancer Research, 2020, 80, 5502-5514.	0.9	31
8	Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia. Leukemia, 2020, 34, 2785-2789.	7.2	4
9	A perivascular niche in the bone marrow hosts quiescent and proliferating tumorigenic colorectal cancer cells. International Journal of Cancer, 2020, 147, 519-531.	5.1	5
10	Transcriptome Profiling of Adipose Tissue Reveals Depot-Specific Metabolic Alterations Among Patients with Colorectal Cancer. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5225-5237.	3.6	21
11	Pheno-seq – linking visual features and gene expression in 3D cell culture systems. Scientific Reports, 2019, 9, 12367.	3.3	16
12	Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model. PLoS ONE, 2019, 14, e0211916.	2.5	27
13	Systematic Generation of Patient-Derived Tumor Models in Pancreatic Cancer. Cells, 2019, 8, 142.	4.1	9
14	The notch target gene HEYL modulates metastasis forming capacity of colorectal cancer patient-derived spheroid cells in vivo. BMC Cancer, 2019, 19, 1181.	2.6	16
15	Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors. Clinical Cancer Research, 2018, 24, 2128-2137.	7.0	88
16	<i>NRG1</i> Fusions in <i>KRAS</i> Wild-Type Pancreatic Cancer. Cancer Discovery, 2018, 8, 1087-1095.	9.4	189
17	Mapping Active Gene-Regulatory Regions in Human Repopulating Long-Term HSCs. Cell Stem Cell, 2018, 23, 132-146.e9.	11.1	14
18	Cell-of-Origin DNA Methylation Signatures Are Maintained during Colorectal Carcinogenesis. Cell Reports, 2018, 23, 3407-3418.	6.4	66

#	Article	IF	Citations
19	Succession of transiently active tumorâ€initiating cell clones in human pancreatic cancer xenografts. EMBO Molecular Medicine, 2017, 9, 918-932.	6.9	36
20	Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer. Journal of Experimental Medicine, 2017, 214, 2073-2088.	8.5	30
21	Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation. International Journal of Cancer, 2017, 140, 1356-1363.	5.1	26
22	Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nature Genetics, 2017, 49, 65-74.	21.4	326
23	Colorectal cancerâ€initiating cells caught in the act. EMBO Molecular Medicine, 2017, 9, 856-858.	6.9	12
24	Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells. Cancer Letters, 2016, 371, 326-333.	7.2	11
25	Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. Nature Communications, 2013, 4, 2610.	12.8	213
26	Specific Elimination of CD133+ Tumor Cells with Targeted Oncolytic Measles Virus. Cancer Research, 2013, 73, 865-874.	0.9	115
27	Transforming Growth Factor Beta Receptor 2 (TGFBR2) Changes Sialylation in the Microsatellite Unstable (MSI) Colorectal Cancer Cell Line HCT116. PLoS ONE, 2013, 8, e57074.	2.5	28
28	Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G _{0/1} phase. Cell Cycle, 2012, 11, 3492-3503.	2.6	21
29	Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. Journal of Experimental Medicine, 2012, 209, 697-711.	8.5	63
30	Stable Long-Term Blood Formation by Stem Cells in Murine Steady-State Hematopoiesis. Stem Cells, 2012, 30, 1961-1970.	3.2	11
31	Extensive Methylation of Promoter Sequences Silences Lentiviral Transgene Expression During Stem Cell Differentiation In Vivo. Molecular Therapy, 2012, 20, 1014-1021.	8.2	87
32	Distinct Types of Tumor-Initiating Cells Form Human Colon Cancer Tumors and Metastases. Cell Stem Cell, 2011, 9, 357-365.	11.1	276
33	You Can Count on This: Barcoded Hematopoietic Stem Cells. Cell Stem Cell, 2011, 9, 390-392.	11.1	10
34	Deregulated EVI1 Expression Leads to Genomic Instability and G1 Cell Cycle Arrest. Blood, 2011, 118, 2431-2431.	1.4	0
35	Hematopoietic activity of human short-term repopulating cells in mobilized peripheral blood cell transplants is restricted to the first 5 months after transplantation. Blood, 2010, 115, 5023-5025.	1.4	3
36	Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nature Medicine, 2010, 16, 198-204.	30.7	727

#	Article	IF	CITATIONS
37	The Inherent Differentiation Program of Short-Term Hematopoietic Repopulating Cells Changes During Human Ontogeny. Stem Cells and Development, 2010, 19, 621-628.	2.1	3
38	Stem-Cell Gene Therapy for the Wiskott–Aldrich Syndrome. New England Journal of Medicine, 2010, 363, 1918-1927.	27.0	505
39	Comprehensive genomic access to vector integration in clinical gene therapy. Nature Medicine, 2009, 15, 1431-1436.	30.7	173
40	Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression. Blood, 2007, 110, 1779-1787.	1.4	16
41	High-resolution insertion-site analysis by linear amplification–mediated PCR (LAM-PCR). Nature Methods, 2007, 4, 1051-1057.	19.0	281
42	Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nature Medicine, 2006, 12, 401-409.	30.7	1,129